Area 2

Genetics and urologic tumors

Team leader

Strategic objectives

Our multidisciplinary research group is focused on the translational research in urological oncology, aimed at generating knowledge that provides a direct benefit to patients in the near future. Specifically, the main objective of our group is to advance in the existing research lines in order to:

  1. Develop non-invasive tools for the diagnosis and prognosis of bladder and prostate cancer.
  2. Identify biomarkers to predict the response to chemotherapy in bladder cancer.
  3. Determine molecular prognostic factors in upper urinary tract tumours. 
Main lines of research

1. Non-invasive diagnosis and prognosis of bladder tumors.

  • Development of a gene/miRNA expression signatures in urine samples.
  • Identification of DNA aneuploidies in urine samples by FISH.
  • Determination of methylation profiles of urine samples. 

2. Predictive biomarkers of prognosis and response to treatments.

  • Markers of disseminated cells from bladder tumours in lymph nodes and peripheral blood.
  • Markers of response to neoadjuvant chemotherapy in bladder cancer patients.
  • Prognostic markers in upper urinary tract tumors.

3. Non-invasive diagnosis and prognosis of prostate tumours.

  • Development of a gene/miRNA expression signature in post-prostatic massage urine samples.
  • Prognostic biomrakers for prostate cancer.